Contact us at technology.development@childrens.harvard.edu for more information.

The Technology Development Fund (TDF) is a seed-stage academic catalyst fund dedicated to translating high-impact, commercially promising academic technologies into the independently-validated, later-stage opportunities to benefit our patients and are often sought by industry partners and investors.

We provide two grants:

  • Pilot Grant | $50,000 to advance early stage technologies in the validation or proof-of-concept stage
  • Development Grant | $150,000 to later-stage technologies whose concept has been proven to add value to the technology and increase its probability to be licensed or to form a startup

Our catalyst fund is open to BCH Principal Investigators only.

Areas of Interest

  • Therapeutics
  • Vaccines
  • Diagnostics
  • Medical Devices

Sanofi is issuing a call-for-proposals for the Sanofi Innovation Awards (iAwards) program, a multi-institutional academic partnership program designed to collaborate with academic investigators to quickly move promising early stage, disease relevant, innovative research towards the clinic. Through this program, Sanofi aims to fund innovative and translational research ideas that can contribute to our early stage pipeline and ultimately benefit patients.Each selected proposal will receive:

  • $125,000 research funding for 12 months
  • Sanofi science expertise and guidance
  • In-kind resources such as reagents, tools, compounds, etc… may be provided
  • Successful projects could be converted to SRAs

Areas of Interest

  • Immunology & Inflammation
  • Rare Diseases
  • Neurological Disorders
  • Genomic Medicine
  • Immuno-Oncology
  • Molecular Oncology
  • Biologics Research


Boston Children’s Hospital and Pfizer Centers for Therapeutic Innovation (CTI) are requesting proposals for novel therapeutic targets with application across Pfizer’s core therapeutic areas.

Areas of Interest

  • Oncology
  • Internal Medicine
  • Inflammation and Immunology
  • Rare Disease

In Scope

  • Novel biological targets supported by:
    • In-vivo and in-vitro models
    • enabling genetics and mechanistic insights
    • translational biochemical or cellular assay and biomarkers
  • Modality agnostic (exception of cell-based therapies)

Out-of-Scope

  • Drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies

Submission Process

  • Develop a 2-3 page non-confidential document outlining the scientific background and research synopsis
  • Pre-proposals should be reviewed by one of Pfizer’s Emerging Science Leads to determine suitability prior to submission, formal submission should be routed through TIDO
  • Deadline: June 28, 2021

Deerfield has pledged up to $65 million with the goal of facilitating the translation and commercialization of novel biomedical research at Boston Children’s Hospital through a new collaboration called Blackfan Circle Innovations. Through Blackfan Circle, Boston Children’s Hospital scientists have the opportunity to submit therapeutic proposals for potential funding.

Deerfield will provide research funding and operational support in product development and commercialization to co-develop the jointly-selected research therapeutic candidates with the goal of achieving Investigational New Drug (IND) readiness. Successful projects that reach IND-enabled status may receive additional funding.

We would like to invite BCH investigators to begin the submission process to Blackfan Circle Innovations, the newly established entity created to accelerate research at BCH.

Areas of Interest:

  • Broad interest across all therapeutic areas and modalities
  • Early-stage projects with potential to progress to IND-enabled status, early clinical development, and human proof-of-concept

Proposal Process:

  • Proposal Concept Sheet
  • Letter of Intent
  • Full Proposal and Presentation

In order to engage initial interest with Blackfan Circle Innovations, TIDO encourages BCH investigators to submit one or more Proposal Concept Sheet(s), each of which will constitute a brief overview of the proposed project focusing on the areas listed below.

  • Genetic Evidence
  • Biologic Rationale
  • Preclinical Execution
  • Unmet Need
  • Clinical Development (if applicable)
  • Novelty/ Differentiation

A Proposal Concept Sheet submission template will be provided by TIDO. For more information on proposal submission to Blackfan Circle Innovations, a copy of the Proposal Concept Sheet, or questions related to the application process, please contact Sabrina Kamran, Strategic Alliance Manager at Sabrina.Kamran@childrens.harvard.edu.

If your Proposal Concept Sheet is selected for advancement, you will be asked to complete a Letter of Intent with a more detailed description of the proposed project. Finally, at the Full Proposal stage of evaluation, you will be asked to submit a detailed research plan and budget and meet with the Deerfield review team to discuss your proposal. Deerfield Discovery and Development experts will be available to consult with you on your proposal throughout the entire evaluation process.

Who Can Apply:

  • Full-time BCH Principal Investigators
  • Principal Investigators with faculty appointment who are subject to Boston Children’s policies regarding the conduct of research and ownership of intellectual property

Submissions:

Proposal Concept Sheets submitted to Blackfan Circle Innovations will be considered on a rolling basis, with operational and scientific guidance and support from TIDO during the submission process.